Literature DB >> 9608406

Changes in seizure threshold over the course of electroconvulsive therapy affect therapeutic response and are detected by ictal EEG ratings.

A D Krystal1, C E Coffey, R D Weiner, T Holsinger.   

Abstract

Therapeutic effectiveness of electroconvulsive therapy is influenced by the degree to which the stimulus intensity exceeds the seizure threshold. However, the threshold rises variably over the treatment course, confounding maintenance of desired relative stimulus intensity. In 47 depressed patients, decreases in relative stimulus intensity between treatments 1 and 6 were associated with diminished therapeutic response at treatment 6 for unilateral (UL) ECT. A multivariate model including manual ratings of ictal EEG data predicted whether seizure threshold rose with 82% accuracy. The same EEG variables were also significantly related to therapeutic response. Thus, decreases in relative stimulus intensity over the ECT course affect the therapeutic potency of UL ECT. Further, ictal EEG indices have considerable potential for predicting such stimulus intensity changes and their effect on therapeutic outcome.

Entities:  

Mesh:

Year:  1998        PMID: 9608406     DOI: 10.1176/jnp.10.2.178

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  18 in total

1.  Seizure threshold increases can be predicted by EEG quality in right unilateral ultrabrief ECT.

Authors:  Verònica Gálvez; Dusan Hadzi-Pavlovic; Susan Waite; Colleen K Loo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-11       Impact factor: 5.270

Review 2.  Meta-analysis of initial seizure thresholds in electroconvulsive therapy.

Authors:  Jeroen A van Waarde; Bastiaan Verwey; Rose C van der Mast
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-04-21       Impact factor: 5.270

3.  An Electrophysiological Biomarker That May Predict Treatment Response to ECT.

Authors:  Katherine W Scangos; Richard D Weiner; Edward C Coffey; Andrew D Krystal
Journal:  J ECT       Date:  2019-06       Impact factor: 3.635

Review 4.  Neuromodulation therapies for geriatric depression.

Authors:  Verònica Gálvez; Kerrie-Anne Ho; Angelo Alonzo; Donel Martin; Duncan George; Colleen K Loo
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

5.  Brief vs. ultrabrief pulse ECT: focus on seizure quality.

Authors:  Isabelle Brunner; Michael Grözinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-07-18       Impact factor: 5.270

6.  Repeated dose titration versus age-based method in electroconvulsive therapy: a pilot study.

Authors:  Jan Jaap Aten; Mardien Oudega; Eric van Exel; Max L Stek; Jeroen A van Waarde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-25       Impact factor: 5.270

7.  Does remifentanil improve ECT seizure quality?

Authors:  Verònica Gálvez; Phern-Chern Tor; Adriana Bassa; Dusan Hadzi-Pavlovic; Ross MacPherson; Mincho Marroquin-Harris; Colleen K Loo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-01       Impact factor: 5.270

Review 8.  Multifactorial determinants of the neurocognitive effects of electroconvulsive therapy.

Authors:  Shawn M McClintock; Jimmy Choi; Zhi-De Deng; Lawrence G Appelbaum; Andrew D Krystal; Sarah H Lisanby
Journal:  J ECT       Date:  2014-06       Impact factor: 3.635

9.  Similar clinical improvement of depression using 0.5-ms and 1-ms pulse widths in bilateral electroconvulsive therapy.

Authors:  Aida de Arriba-Arnau; Virginia Soria; Neus Salvat-Pujol; José M Menchón; Mikel Urretavizcaya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-12-13       Impact factor: 5.270

Review 10.  Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yoshiteru Takekita; Taro Suwa; Naotaka Sunada; Hirotsugu Kawashima; Chiara Fabbri; Masaki Kato; Aran Tajika; Toshihiko Kinoshita; Toshi A Furukawa; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-01-28       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.